About Waters Corporation ( www.waters.com )For more than 50 years, Waters Corporation has created business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality, consumer products and high-value added chemicals worldwide. Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success. With revenue of $1.9 billion in 2013, Waters is driving scientific discovery and operational excellence for customers worldwide. Waters, Xevo, UPLC, UPC 2, ACQUITY, UNIFI, and ACQUITY UPLC are trademarks of Waters Corporation.
Waters Corporation (NYSE: WAT) today announced an agreement with the Chinese Pharmacopoeia Commission (ChP) to establish a Joint Open Laboratory. Scheduled to open before the end of 2014, the new Joint Open Laboratory will focus on in-depth research of pharmacopoeia standards, development of testing methods, methods validations and basic and advanced technical training of pharmacopoeia detection methods. Both the ChP and Waters ® expect the laboratory to become one of the national technical support centers in the field of Chinese pharmaceutical standards. "Waters is very excited about our new collaboration with the Chinese Pharmacopeia Commission," said Art Caputo, President of the Waters Division. "I am confident that this new Joint Open Laboratory will make positive contributions to assuring drug quality control in China, it will quickly become an international leader in the field of traditional Chinese pharmaceutical standards." At the collaboration agreement signing ceremony in Beijing, Secretary General Zhang Wei of the ChP pointed out that "the ChP-Waters Joint Open Laboratory cooperation would become another milestone of the development of the ChP. This cooperation not only meets the needs of ChP’s own development, but also meets the demands of enhanced pharmacopoeia standards and improved public drug safety." Located in the laboratory building of Beijing Zhendong Guangming Drug Research Institute, the new Joint Open Laboratory is more than 400 square meters (more than 1300 square feet). The laboratory will be outfitted with a full complement of Waters chromatography and mass spectrometry technologies, including (but not limited to) a range of ACQUITY UPLC ® systems, ACQUITY UPC 2® System, Xevo ® tandem quadrupole and time-of-flight mass spectrometers, and a Natural Products Application Solution with UNIFI ®. About Chinese Pharmacopeia Commission Commonly referred to as ChP, the Chinese Pharmacopeia Commission is an official and authoritative compendium of drugs and has been in place since 1950 – publishing compendiums in 1953, 1963, 1977, 1985, 1990, 1995, 2000, 2005, and 2010. Formerly reporting under the Chinese Ministry of Health, it is now is an affiliated commission of the newly formed Chinese Food and Drug Administration (CFDA). The Chinese Pharmacopeia Commission is also officially recognized by the World Health Organization.